{"slug":"thymosin-alpha-1-post-surgery","verification":{"valid":true,"entries":1,"head":"5ee94409ef17f74be3ee42073cb2d82ff6117e386de38b00edce1b349cb34234"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.05403,"waste_cost_usd":0,"total_tokens":39372,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.05403,"tokens_total":39372,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:59:03.629Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Thymosin Alpha 1 for Post-Surgery: Immune Modulation Evidence Review","register":"source_ledger","body":"## What's breaking down\n\nPost-surgery, the body experiences acute tissue trauma from incisions, tissue manipulation, and blood loss. This triggers a stress response that often suppresses certain immune functions while ramping up inflammation. T-cell activity can drop, natural killer cell function may decline, and the risk of postoperative infections rises because the immune system is temporarily dysregulated rather than fully coordinated for repair.\n\nIf immune balance does not recover promptly, tissue healing slows, hospital stays extend, and complications like wound infections or organ stress become more likely. The core issue is not just the wound itself but whether repair pathways outpace ongoing breakdown from inflammation and opportunistic pathogens. Thymosin Alpha 1 is discussed in this context for its studied effects on immune cell coordination, not as a pain mask or direct wound sealant.\n\n## Why Thymosin Alpha 1 might help you\n\nIf immune dysregulation after surgery is part of your situation, Thymosin Alpha 1 is examined because it targets immune restoration pathways that support tissue repair coordination. Here is the logic chain:\n\n1. Surgical trauma commonly reduces CD4+ T-cell counts and shifts immune balance toward suppression.\n2. Thymosin Alpha 1 has been observed in human studies to increase CD4+ percentages and improve CD4+/CD8+ ratios.\n3. Better T-cell balance is linked in those studies to lower rates of certain infections and improved markers of recovery.\n4. Therefore for you: If that immune layer is limiting your post-operative repair, the compound is studied for restoring coordination rather than suppressing symptoms.\n\nIt does not replace standard post-surgical care such as wound management or antibiotics when indicated.\n\n## How these fit together\n\nThis is a single-compound focus. Thymosin Alpha 1 addresses the immune modulation layer. In broader contexts where multiple degeneration layers exist (such as inflammation plus tissue integrity), other agents might target separate steps, but here the discussion centers on immune restoration after surgical stress.\n\n## What the evidence actually shows\n\nHuman data includes a 2024 study of 180 colorectal cancer patients after radical surgery. Those receiving Thymosin Alpha 1 plus chemotherapy showed improved immune markers, lower neutropenia incidence, and reduced three-year recurrence compared with chemotherapy alone (human trial). Another analysis of HBV-related hepatocellular carcinoma patients after curative resection found improved postoperative survival in propensity-matched groups receiving the compound as adjuvant (human observational).\n\nA multicenter randomized protocol (PANDA II) is examining Thymosin Alpha 1 for immune response and organ function after acute aortic dissection repair, but results are not yet available (ongoing human trial protocol).\n\nLarger sepsis trials provide mixed context. A 2025 phase 3 double-blind placebo-controlled trial with 1,106 adults found no statistically significant reduction in 28-day mortality (23.4% vs 24.1%) (human trial). Earlier smaller studies had suggested possible benefits in organ dysfunction markers.\n\nA 2024 narrative review summarized over 11,000 human subjects across more than 30 trials and described a generally favorable safety profile in varied settings including cancer adjunct and infection recovery (human data compilation).\n\nPreclinical (animal) work supports immune cell maturation effects, but human postoperative-specific trials remain limited beyond oncology resection contexts.\n\n## What scientists say\n\nReviews describe Thymosin Alpha 1 as an immunomodulator that can enhance T-cell differentiation and dendritic cell activity without broad overstimulation. Researchers note its historical use in certain countries as an adjunct in viral hepatitis and oncology settings where immune recovery after treatment is relevant. They emphasize that large confirmatory trials are still needed for many indications, including routine post-surgical use (mechanistic and human review sources).\n\n## What people say on Reddit\n\nAnecdotal reports on Reddit focus more on chronic immune or post-viral issues than direct post-surgery experiences. Users in MCAS or CFS communities mention perceived improvements in energy or symptom stability after courses of the compound, with some noting short-term side effects like injection site discomfort or transient symptom flares. Specific post-operative recovery stories are sparse; most threads discuss dosing frequency or sourcing rather than surgical outcomes (anecdotal).\n\n## What people say on X\n\nPosts on X are limited and largely promotional or general. One account highlighted potential recovery support after illness or surgery via immune coaching effects. No large volume of verified user surgical anecdotes appears in recent searches (anecdotal).\n\n## What we do not know\n\nDirect large-scale randomized trials specifically for common elective surgeries (such as orthopedic or abdominal procedures in non-cancer patients) are absent. Long-term effects on recurrence or healing quality beyond oncology settings remain understudied. Optimal timing relative to surgery and interactions with common perioperative medications are not fully mapped in published data. Individual response variability based on age, comorbidities, or baseline immune status is acknowledged but not quantified for post-surgical populations.\n\n## Safety and limits\n\nAcross the reviewed human trials involving thousands of participants, the compound is generally described as well tolerated with low rates of serious adverse events attributable to it. Common reports include mild injection-site reactions. The 2025 sepsis trial reported similar overall adverse event rates between active and placebo arms. Quality of compounded products varies and is outside regulated pharmaceutical channels in many regions. No claims of disease treatment or prevention are made here; evidence grading shows human data concentrated in specific oncology and infection contexts with gaps elsewhere (human safety data).\n\nAll information is for research discussion only. Consult qualified medical professionals for personal health decisions.","claims":[{"id":"c1","text":"A 2024 human study of 180 colorectal cancer patients post-radical surgery found Thymosin Alpha 1 plus XELOX improved immune function and lowered three-year recurrence vs XELOX alone.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Provides direct human postoperative data on immune and recurrence outcomes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:59:03.179Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A 2025 phase 3 human trial of 1,106 sepsis patients found no significant 28-day mortality reduction with Thymosin Alpha 1 vs placebo (23.4% vs 24.1%).","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Large recent RCT provides high-quality negative mortality data for context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:59:03.179Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"A 2024 narrative review summarized safety and efficacy across over 11,000 human subjects in more than 30 trials involving Thymosin Alpha 1.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Broad human evidence base for safety grading.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:59:03.179Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"PANDA II is an ongoing multicenter randomized human trial protocol testing Thymosin Alpha 1 after acute aortic dissection surgery for immune and organ function effects.","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Direct relevance to major post-surgical immune recovery.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:59:03.179Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Propensity-matched human analyses in HBV-related HCC post-resection showed improved postoperative survival with Thymosin Alpha 1 adjuvant use.","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Additional human resection recovery data.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:59:03.179Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit anecdotes on Thymosin Alpha 1 primarily concern MCAS, CFS, or long COVID rather than specific post-surgical recovery.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s6"],"source_status":"sourced","why_material":"Documents limited surgical-specific user reports.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:59:03.179Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c7","text":"X posts mentioning Thymosin Alpha 1 in recovery contexts are sparse and mostly promotional.","section":"What people say on X","tier":"anecdotal","source_ids":["s7"],"source_status":"sourced","why_material":"Confirms low volume of relevant anecdotes.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:59:03.179Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11017181/","title":"Thymosin α1 combined with XELOX improves immune function and reduces serum tumor markers in colorectal cancer patients after radical surgery","quote":"Thymosin α1 combined with XELOX is effective in improving immune function, reducing serum tumor markers, and minimizing recurrence in CRC patients after radical surgery.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://www.bmj.com/content/388/bmj-2024-082583","title":"The efficacy and safety of thymosin α1 for sepsis (TESTS)","quote":"28 day all cause mortality occurred in 127 participants (23.4%) in the thymosin α1 group and 132 (24.1%) in the placebo group","link_status":"http_403","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38308608/","title":"Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials","quote":"This study aims to assess the safety and efficacy of Thymosin Alpha 1 (Tα1) through a comprehensive narrative review of clinical studies involving over 11 000 human subjects in more than 30 trials.","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"pubmed","url":"https://www.tandfonline.com/doi/abs/10.1080/14796678.2025.2505401","title":"Effect of thymosin α1 on Immune response and organ function in acute aortic dissection surgery: PANDA II trial protocol","quote":"This multicenter randomized controlled trial evaluates the efficacy of thymosin alpha 1 (Tα1) supplementation in preventing organ dysfunction following acute type A aortic dissection (ATAAD) repair.","link_status":"http_403","quote_status":"unverified"},{"id":"s5","type":"pubmed","url":"https://www.sciencedirect.com/science/article/abs/pii/S1567576923002722","title":"Thymosin alpha 1 – Reimagine its broader applications","quote":"Recent studies showed that Tα1 could significantly improve overall survival (OS) in patients with surgically resectable non-small cell lung cancer (NSCLC) and liver cancers in the adjuvant setting.","link_status":"http_403","quote_status":"unverified"},{"id":"s6","type":"reddit","url":"https://www.reddit.com/r/MCAS/comments/1mcx0o3/peptide_called_thymosin_alpha_1_is_resolving_my/","title":"Peptide called Thymosin Alpha 1 is resolving my MCAS","quote":"Peptide called Thymosin Alpha 1 is resolving my MCAS","link_status":"ok","quote_status":"unverified"},{"id":"s7","type":"x","url":"https://x.com/WellnessIvDrip/status/1968796485576777945","title":"X post on recovery after surgery","quote":"After illness or surgery, recovery drags instead of resetting quickly. Thymosin Alpha-1 is a natural peptide that coaches your immune system.","link_status":"http_404","quote_status":"unverified"}]},"rationale":"","tokens_in":35520,"tokens_out":3852,"cost":0.05403,"prev_hash":"genesis","hash":"5ee94409ef17f74be3ee42073cb2d82ff6117e386de38b00edce1b349cb34234"}]}